Eli Lilly agreed on November 16, 2026 to acquire Calytrix Bio, a privately held biotech in Wellesley Hills, Massachusetts, that is developing treatments for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. Calytrix shareholders could receive up to $1.5 billion in cash.
That figure combines an upfront payment with further payments that depend on reaching certain clinical and regulatory milestones. Calytrix, which announced the agreement, did not say how large the upfront payment is or when it expects the deal to close.
Calytrix's chief executive, Brad Prosek, said he expected Lilly to take the company's antibody programme into clinical trials and to study its use across the range of the disease.
What Calytrix is developing
The company's lead drug candidate is a biparatopic antibody, meaning it binds to two different sites on the same protein. Its target is a mutated form of calreticulin, called mCALR, which drives some cases of essential thrombocythemia (ET) and myelofibrosis (MF). Calytrix designed the antibody to act against both of the main mutation types, known as Type 1 and Type 2.
Because the mutant protein appears on the surface of the cancerous cells and not on healthy ones, Calytrix argues that it can be used to wipe out the disease-causing clone of cells while leaving normal tissue and healthy blood production alone. The company said it also wants the drug to be safe and convenient enough to be given early in the disease and over long periods.
The programme is still preclinical. Calytrix said existing drugs for ET and MF mostly manage symptoms and complications. BioPharma Dive noted that those treatments include blood transfusions and JAK inhibitors such as Incyte's Jakafi.
Calytrix argued that this leaves room for precision drugs aimed at the mutations that drive the disease. Prosek said the company's goal from the start had been to change the course of mCALR-driven ET and MF, not just to treat its effects.
“Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms. From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision.”
The founders and the funding
J.P. Morgan Life Sciences Private Capital, the life sciences venture capital arm of J.P. Morgan Asset Management, founded Calytrix in 2025. The company started with a Series A round co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners, and later raised a Series B led by Avoro Ventures. The size of neither round was disclosed.
Prosek is president and chief executive. Centerview Partners acted as Calytrix's exclusive financial adviser and Goodwin Procter as its legal counsel. Paul, Weiss advised Lilly, with a team led by corporate partners Krishna Veeraraghavan and Chelsea Darnell and intellectual property partner Jeffrey Osterman, according to the law firm.
Prosek thanked Calytrix's staff, scientific advisers and investors, saying their support had brought the programme to the point where clinical development can begin. Calytrix did not disclose its headcount or what roles its employees will have at Lilly.
Paul, Weiss said its team for Lilly also included partners covering antitrust, intellectual property, executive compensation, tax and litigation.
Why Lilly is buying
Calytrix said the purchase widens Lilly's position in MPNs and builds on the drugmaker's existing work in blood cancers. Dealroom pointed out that Lilly already sells Jaypirca, a blood cancer drug, and that earlier in 2026 it agreed to pay $2.3 billion for Ajax Therapeutics.
Lilly is not alone in chasing mCALR. Dealroom named Galecto as another company working on mutant calreticulin-driven disease.
The announcement did not say whether Calytrix's Wellesley Hills team will stay in place after the deal closes, or what Lilly expects to spend on taking the antibody through clinical trials.
Lilly's year of deals
The agreement was Lilly's 15th announced company acquisition of 2026, BioPharma Dive reported, taking its spending on such deals this year past $30 billion. Most of those targets were privately held startups.
That pace has made Lilly the most active buyer of drug companies this year. BioPharma Dive said GSK, Gilead Sciences and Novartis were the next most active, with three purchases each.
For J.P. Morgan's venture arm, the sale is a fast exit: Calytrix was founded last year and its antibody has not entered human trials. The final value to shareholders will depend on how far the drug advances in Lilly's hands.




